341 related articles for article (PubMed ID: 25081546)
1. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
[TBL] [Abstract][Full Text] [Related]
2. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy.
Dillon KE; Sammel MD; Prewitt M; Ginsberg JP; Walker D; Mersereau JE; Gosiengfiao Y; Gracia CR
Fertil Steril; 2013 Feb; 99(2):477-83. PubMed ID: 23084267
[TBL] [Abstract][Full Text] [Related]
4. Impact of breast cancer on anti-mullerian hormone levels in young women.
Su HI; Flatt SW; Natarajan L; DeMichele A; Steiner AZ
Breast Cancer Res Treat; 2013 Jan; 137(2):571-7. PubMed ID: 23224236
[TBL] [Abstract][Full Text] [Related]
5. Impact of cancer therapies on ovarian reserve.
Gracia CR; Sammel MD; Freeman E; Prewitt M; Carlson C; Ray A; Vance A; Ginsberg JP
Fertil Steril; 2012 Jan; 97(1):134-40.e1. PubMed ID: 22137491
[TBL] [Abstract][Full Text] [Related]
6. Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age.
Steiner AZ; Pritchard D; Stanczyk FZ; Kesner JS; Meadows JW; Herring AH; Baird DD
JAMA; 2017 Oct; 318(14):1367-1376. PubMed ID: 29049585
[TBL] [Abstract][Full Text] [Related]
7. Limited value of ovarian function markers following orthotopic transplantation of ovarian tissue after gonadotoxic treatment.
Janse F; Donnez J; Anckaert E; de Jong FH; Fauser BC; Dolmans MM
J Clin Endocrinol Metab; 2011 Apr; 96(4):1136-44. PubMed ID: 21289248
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
[TBL] [Abstract][Full Text] [Related]
9. Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
Henry NL; Xia R; Schott AF; McConnell D; Banerjee M; Hayes DF
Oncologist; 2014 Jan; 19(1):68-74. PubMed ID: 24319018
[TBL] [Abstract][Full Text] [Related]
10. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure.
Knauff EA; Eijkemans MJ; Lambalk CB; ten Kate-Booij MJ; Hoek A; Beerendonk CC; Laven JS; Goverde AJ; Broekmans FJ; Themmen AP; de Jong FH; Fauser BC;
J Clin Endocrinol Metab; 2009 Mar; 94(3):786-92. PubMed ID: 19066296
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
Anderson RA; Cameron DA
J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
[TBL] [Abstract][Full Text] [Related]
12. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L
Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China.
Wang S; Pei L; Hu T; Jia M; Wang S
Hum Reprod; 2021 Mar; 36(4):976-986. PubMed ID: 33411897
[TBL] [Abstract][Full Text] [Related]
14. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
[TBL] [Abstract][Full Text] [Related]
15. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
Oktay KH; Bedoschi G; Goldfarb SB; Taylan E; Titus S; Palomaki GE; Cigler T; Robson M; Dickler MN
Fertil Steril; 2020 Jun; 113(6):1251-1260.e1. PubMed ID: 32331767
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of serum anti-mullerian hormone and inhibin B in prediction of ovarian response in patients with polycystic ovary syndrome.
Zhang F; Liu XL; Rong N; Huang XW
J Huazhong Univ Sci Technolog Med Sci; 2017 Feb; 37(1):70-73. PubMed ID: 28224431
[TBL] [Abstract][Full Text] [Related]
17. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
[TBL] [Abstract][Full Text] [Related]
18. Serum anti-müllerian hormone levels in evaluation of chemotherapy effect on ovarian reserve in women with breast cancer. A follow-up study.
Al-Rawi SA; Saleh BO; Al-Naqqash MA
Saudi Med J; 2018 Jul; 39(7):733-735. PubMed ID: 29968900
[TBL] [Abstract][Full Text] [Related]
19. Updated assays for inhibin B and AMH provide evidence for regular episodic secretion of inhibin B but not AMH in the follicular phase of the normal menstrual cycle.
Randolph JF; Harlow SD; Helmuth ME; Zheng H; McConnell DS
Hum Reprod; 2014 Mar; 29(3):592-600. PubMed ID: 24357435
[TBL] [Abstract][Full Text] [Related]
20. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age.
Rosendahl M; Andersen CY; la Cour Freiesleben N; Juul A; Løssl K; Andersen AN
Fertil Steril; 2010 Jun; 94(1):156-66. PubMed ID: 19342041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
